The Effect of Reduced Liver Function on Selatogrel Pharmacokinetics

NCT ID: NCT04406896

Last Updated: 2025-07-04

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 24 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-07-22
• Study Completion Date: 2020-10-23

Brief Summary

This is a prospective, single-center, open-label, single-dose, Phase 1 study, to assess the effect of mild and moderate hepatic impairment due to liver cirrhosis on the pharmacokinetics of selatogrel (ACT-246475).

Conditions

Healthy Subjects; Hepatic Impairment

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

Participants with mild hepatic impairment (Group 1)

Participant with Child-Pugh Grade A Score of 5-6.

Group Type: EXPERIMENTAL

Selatogrel

Intervention Type: DRUG

A single subcutaneous injection of 16 mg.

Participants with moderate hepatic impairment (Group 2)

Participant with moderate hepatic impairment with a Child-Pugh Grade B Score of 7-9.

Group Type: EXPERIMENTAL

Selatogrel

Intervention Type: DRUG

A single subcutaneous injection of 16 mg.

Healthy participants (Group 3)

Group Type: EXPERIMENTAL

Selatogrel

Intervention Type: DRUG

A single subcutaneous injection of 16 mg.

Interventions

Selatogrel

A single subcutaneous injection of 16 mg.

Intervention Type: DRUG

Other Intervention Names

ACT-246475

Eligibility Criteria

Inclusion Criteria

All participants (Groups 1,2 and 3)

• Signed informed consent in a language understandable to the participant prior to any study-mandated procedure.
• Male or female participant aged between 18 and 79 years (inclusive) at screening.
• Body mass index of 18.0 to 35.0 kg/m2 (inclusive) at screening.
• Women of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test on Day 1 (pre-dose). They must consistently and correctly use (from screening, during the entire study, and for at least 30 days after last study treatment administration) an acceptable effective method of contraception method, be sexually inactive, or have a vasectomized partner. If a hormonal contraceptive is used, it must have been initiated at least 1 month before treatment administration.
• Women of non-childbearing potential.

• Hepatic impairment due to liver cirrhosis according to the Child-Pugh classification:

• Group 1: Mild hepatic impairment, Child-Pugh A = score 5-6.
• Group 2: Moderate hepatic impairment, Child-Pugh B = score 7-9.
• Systolic blood pressure (SBP) 95-160 mmHg, diastolic blood pressure (DBP) 60-95 mmHg, and pulse rate 50-100 bpm (inclusive), measured on the same arm, after 5 minutes in the supine position at screening and on Day 1 (pre-dose).
• Estimated glomerular filtration rate (eGFR) at screening using the Modification of Diet in Renal Disease (MDRD) formula of:

• greater than or equal to 60 mL/min/1.73 m2 for participants with mild hepatic impairment (Group 1)
• greater than or equal to 45 mL/min/1.73 m2 for participants with moderate hepatic impairment (Group 2).
• Stable concomitant medications for at least 3 weeks prior to screening and up to Day 1 and expected to be stable during the conduct of the study.

• Normal blood pressure measured on the same arm, after 5 minutes in the supine position at screening and on Day 1 pre-dose defined as:

• SBP 90 to 140 mmHg, DBP 60 to 90 mmHg, and pulse rate 50 to 100 bpm (inclusive) for participants less than 60 years of age.
• SBP 95 to 160 mmHg, DBP 65 to 95 mmHg, and pulse rate 50 to 100 bpm (inclusive) for participants 60 years and older.
• eGFR greater than or equal to 80 mL/min/1.73 m2 at screening using the MDRD formula.

Exclusion Criteria

All participants (Groups 1, 2 and 3)

• Pregnant or lactating woman.
• Previous exposure to selatogrel.
• Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.
• Known hypersensitivity to P2Y12 receptor antagonists or any excipients of the drug formulation.
• Known platelet disorders.
• Legal incapacity or limited legal capacity at screening.

• History or clinical evidence of any disease and/or existence of any surgical or medical condition (e.g., cholecystectomy), which might interfere with the absorption, distribution, metabolism, and excretion (ADME) of the study treatment (except for hepatic impairment, appendectomy, and herniotomy).
• Acute hepatitis, hepatic cancer, primary biliary cirrhosis, or any form of cholestatic disease.
• Clinical evidence or suspected acute liver failure as judged by the investigator.
• Severe ascites and/or pleural effusion.
• Encephalopathy greater than grade 2.
• Clinical evidence of current alcohol or drug abuse.
• Clinically relevant abnormalities on a 12-lead ECG, except for abnormalities related to hepatic impairment, after 5 minutes in the supine position at screening and on Day 1 pre-dose.

• History or clinical evidence of any disease and/or existence of any surgical or medical condition (e.g., cholecystectomy), which might interfere with the ADME of the study treatment (except for appendectomy and herniotomy).
• History or clinical evidence of alcohol or drug abuse within the 3 years prior to screening.
• Family or personal history of prolonged bleeding or bleeding disorders, intracranial vascular diseases, stroke, reasonable suspicion of vascular malformations, or peptic ulcers.
• Previous treatment with any prescribed medications or over-the-counter medications within 2 weeks or 5 times the terminal half-life (t½), whichever is longer prior to study treatment administration (excludes contraceptives and hormone replacement therapy).

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 79 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Viatris Innovation GmbH

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Clinical Trials

Role: STUDY_DIRECTOR

Viatris Innovation GmbH

Locations

CRS Clinical Research Services

Kiel, , Germany

Countries

Germany

Other Identifiers

2020-001315-25

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

ID-076-108

Identifier Type: -

Identifier Source: org_study_id